



Date: 15<sup>th</sup> May, 2026

**To,**  
Corporate Relations Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
**Company Code: ACCPL**

Dear Sir/ Madam,

**Subject: Media Release for the year ended on 31<sup>st</sup> March, 2026**

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the media release of our Company for the year ended on 31<sup>st</sup> March, 2026, the content of which is self-explanatory.

You are requested to kindly take on your record.

Thanking You.

Yours truly,  
**For Accretion Pharmaceuticals Limited**

**Roshni Shah**  
**Company Secretary and Compliance Officer**

Encl.: As above

## Media Release

### **Company Delivers Robust Performance in H2 FY26: Revenue up 18.24% YoY and EBITDA up 4.50%**

#### **Growth Led by Volume Expansion and an Improved Product Mix, along with Wider Customer Base and Geographic Reach**

**Ahmedabad, 15<sup>th</sup> May, 2026:** Accretion Pharmaceuticals Limited (NSE Emerge: ACCPL), a leading manufacturer of high-quality pharmaceutical formulations and contract development and manufacturing organization (CDMO) services, announced its Audited financial results for the year ended 31<sup>st</sup> March, 2026.

#### **Key Financial Highlights (Rs. In Crore):**

Particulars	H2 FY26	H2 FY25	YoY %	H1 FY26	FY26	FY25	YoY %
Net Revenue	<b>45.89</b>	38.81	18.24%	43.74	<b>89.63</b>	57.38	56.21%
EBIDTA*	<b>7.88</b>	7.54	4.50%	7.07	<b>14.95</b>	11.88	25.85%
EBIDTA Margin %	<b>17.17%</b>	19.43%	(226 Bps)	16.17%	<b>16.68%</b>	20.71%	(403 Bps)
PAT	<b>4.92</b>	4.33	13.55%	4.75	<b>9.67</b>	6.79	42.30%
PAT Margin %	<b>10.71%</b>	11.15%	(44 Bps)	10.87%	<b>10.79%</b>	11.84%	(105 Bps)

\*Excluding Other Income

#### **Financial Results Highlights for the Half year ended 31<sup>st</sup> March 2026:**

- **Net revenue in H2 FY26 stood at Rs. 45.89 crore, as against Rs. 38.81 crore in H2 FY25, YoY growth of 18.24%**, driven by healthy volume growth and an improved product mix—supported by new customer additions, ongoing product registrations under approval across multiple geographies, and better utilisation of IPO-funded capacities.
  - ✓ **Contribution from Export at 7.98%**
- **EBITDA (excluding other income) was Rs. 7.88 crore in H2 FY26 as against Rs. 7.54 crore in H2 FY25, YoY growth of 4.50%, with an EBITDA margin of 17.17% in H2 FY26.** EBITDA growth was moderated due to higher manpower costs linked to team expansion for dossier preparation, regulatory and business development activities undertaken to support future growth, alongside raw material price variations arising from global market disruptions.

- **EBITDA Margin for the half year stood at 17.17%.** Margins were impacted by raw material price inflation arising from global market disruptions and geopolitical uncertainties, higher manpower costs for regulatory and business development activities, increased customer acquisition efforts, and one-time IPO-related expenses incurred during the year.
- **Profit After Tax rose by 13.55% YoY to Rs. 4.92 crore in H2 FY26, with a PAT margin of 10.71%.** The increase was supported by revenue-led operating profit growth and a meaningful reduction in finance costs following debt repayment from IPO proceeds and improved working-capital.

**Financial Results Highlights for the Year ended 31<sup>st</sup> March 2026:**

- **Net revenue in FY26 stood at Rs. 89.63 crore,** as against **Rs. 57.38 crore in FY25,** YoY growth of **56.21%**, driven by strong volume expansion and an improved product mix, with the Oral Liquid and Tablet categories contributing the most. Growth was further aided by new customer additions, ongoing product registrations across multiple markets, and better utilisation of capacities funded through the IPO.
  - ✓ **Contribution from Export at 8.56%**
- **EBITDA (excluding other income) was Rs. 14.95 crore in FY26 as against Rs. 11.88 crore in FY25, YoY growth of 25.85%.** EBITDA growth trailed revenue growth largely on account of higher manpower costs, IPO-related expenses incurred during the year, and raw material price variations stemming from global market disruptions.
- **EBITDA Margin for the year stood at 16.68%.** Higher input costs and initial scaling up expenses exerted pressure on margins.
- **Profit After Tax rose 42.30% YoY to Rs. 9.67 crore in FY26, with a PAT margin of 10.79%.**

**Management Comment:**

Commenting on the Company's performance, **Mr. Vivek Ashok Kumar Patel, Promoter, Managing Director, Accretion Pharmaceuticals Limited** said:

*"We are pleased to report a strong financial and operational performance for FY26, marked by robust revenue growth and continued expansion across key business areas. During the year, the*



*Company achieved a total income of ₹89.63 crore, reflecting a growth of 56.21% YoY, while Profit After Tax increased by 42.30% YoY to ₹9.67 crore. The growth was primarily driven by volume expansion and an improved product mix, particularly in the Oral Liquid and Tablet categories, which continued to witness healthy demand across markets.*

*FY26 has been a year of strong operational progress and strategic execution for Accretion Pharmaceuticals Limited. We continued to witness robust demand momentum across our core export markets, supported by a healthy order book, expanding product portfolio, and increasing penetration in Africa, Latin America, and Southeast Asia.*

*During the year, we focused on scaling our CDMO capabilities and improving capacity utilization across key dosage forms, which has enabled us to deliver consistent revenue growth. While margins during the year were impacted by product mix changes, upfront investments in product registrations, and compliance-related costs, we remain confident of a gradual improvement in profitability as these investments begin to yield results and operating leverage improves.*

*Our export-led strategy continues to be a key growth driver, with ongoing efforts to transition towards higher- margin direct exports and expand into new geographies. With over 100 products under registration and multiple market approvals underway, we are well positioned to deepen our presence in existing regions while unlocking new opportunities.*

*Looking ahead, we remain focused on driving sustainable growth through enhanced capacity utilization, continued investments in product development and registrations, and strengthening our global partnerships. We are confident that our disciplined approach, strong execution capabilities, and expanding international footprint will enable us to deliver long-term value for all stakeholders.*

*Thank you for your ongoing support and trust in Accretion Pharmaceuticals Limited”*

## Company Overview

Accretion Pharmaceuticals Limited, established in 2012 and headquartered in Ahmedabad, Gujarat, India, is a fast-growing pharmaceutical company listed on the NSE Emerge platform (since May 21, 2025). Specializing in the development, manufacturing, and marketing of high-quality generic and branded formulations, the Company offers a diverse portfolio including tablets, capsules, oral liquids, oral powder and external preparation. Operating from a state-of-the-art facility at Xcelon Industrial Park, Sanand, Ahmedabad, Gujarat, India. Accretion provides contract development and manufacturing organization (CDMO) services, private labeling, and third-party manufacturing for merchant exporter, domestic marketer and international clients.

Our Company is WHO- cGMP, GLP, Cambodia GMP, Rwanda GMP, Nigeria GMP, Malawi GMP, ISO 9001:2015, ISO 14001:2015 and ISO 22000:2018 certified and is led by an experienced board of directors, and a professional and experienced management team with extensive experience in the pharmaceutical.

**For more details please visit:** [www.accretionpharma.com](http://www.accretionpharma.com)

*For further information please contact:*

<p><i>Company:</i></p> <p><b>Roshni Shah</b></p> <p>Company Secretary &amp; Compliance Officer</p> <p>Accretion Pharmaceuticals Limited</p> <p>E-mail: <a href="mailto:compliance@accretionpharma.com">compliance@accretionpharma.com</a></p>	<p><i>Investor Relations:</i></p> <p><b>Rupesh Rege</b></p> <p><b>Chaitanya Satwe</b></p> <p><b>Mousami Chavan</b></p> <p>Adfactors PR Pvt. Ltd.</p> <p>Email: <a href="mailto:rupesh.rege@adfactorspr.com">rupesh.rege@adfactorspr.com</a>  <a href="mailto:chaitanya.satwe@adfactorspr.com">chaitanya.satwe@adfactorspr.com</a>  <a href="mailto:mousami.chavan@adfactorspr.com">mousami.chavan@adfactorspr.com</a></p>
---	---

**Note:** Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.